𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tamoxifen modulation of cisplatin resistance in patients with metastatic melanoma a biologically important observation

✍ Scribed by Edward F. Mc Clay; Mary Eileen T. Mc Clay; Kathleen D. Albright; Jeffrey A. Jones; Randolph D. Christen; John Alcaraz; Stephen B. Howell

Book ID
102674534
Publisher
John Wiley and Sons
Year
1993
Tongue
English
Weight
517 KB
Volume
72
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A Phase I and pharmacokinetic study of h
A Phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma
✍ Edward F. McClay; Mary-Eileen T. McClay; Jeffery A. Jones; Paul J. Winski; Rando πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 97 KB πŸ‘ 2 views

by 40 mg to the MTD in groups of 3 patients. DDP (80 mg/m 2 ) was begun on Day ogy/Oncology, Hollings Cancer Center, Medical 2 and repeated weekly for a total of 3 weeks. During Week 4, the patients were University of South Carolina, Charleston, South not treated with DDP but instead evaluated for r

Phase II trial of tamoxifen, etoposide,
Phase II trial of tamoxifen, etoposide, mitoxantrone, and cisplatin in patients with metastatic breast carcinoma
✍ Suzanne D. Conzen; Peter A. Kaufman; Christine Arvizu; Paul LeMarbre; L. Herbert πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 554 KB

## BACKGROUND. Based on previous data demonstrating a potentially synergistic interaction between tamoxifen and cisplatin in metastatic melanoma therapy, a Phase I1 study was performed to assess the activity of tamoxifen, etoposide, mitoxantrone, and cisplatin (TEMP) in patients with metastatic br